BioSpace News Archive

Hansa Biopharma announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting on May 12, 2021 and has the following composition.

Oncopeptides AB . According to the principles for the appointment of the Nomination Committee in Oncopeptides AB, the Nomination Committee for the annual general meeting 2022 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of September 30, along with the Chairman of the Board of Directors.

BD, a leading global medical technology company, will begin its Investor Day at 8 a.m. ET to share how it plans to leverage the breadth and depth of its core portfolio to fuel a new wave of growth through transformative solutions that can help reinvent health care.

Clearday, Inc. (OTCQB: CLRD) today announced a Joint venture with Invento Research Inc., an ISO 9001:2015 certified company, to bring the latest robotic technology to the senior care world.

PLx Pharma Inc. announced today certain financial and operational results for the three and nine months ended September 30, 2021.

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the poster presentation of preclinical data for RTX-224.

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), today announced updated results from its Phase 1/1b clinical trial of mupadolimab (formerly CPI-006), a humanized monoclonal antibody directed against CD73 with a proposed unique mechanism of activating B cells to generate immune responses to tumor antigens and viruses, and inhibiting the production of immunosuppressive adenosine in the tumor microenvironment.

Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced the presentation of final clinical data from the Phase 1b study, CMP-001-001 (NCT02680184), of vidutolimod.

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the first preclinical data for SNS-101, its anti-VISTA (V-domain Ig suppressor of T cell activation) product candidate.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, reported financial results for the third quarter ended September 30, 2021.